Multimodal Pain Management in Senior Patients: Building Protocols That Actually Work
Chronic pain in senior dogs and cats is one of the most undertreated conditions in veterinary medicine, and the gap is rarely about recognition. Most clinicians can identify the arthritic dog who struggles on cold mornings or the cat who has stopped grooming her hindquarters. The harder clinical challenge is building a treatment plan that addresses the full complexity of what that patient is experiencing, navigating drug interactions, comorbidities, species-specific contraindications, and the real-world constraints of what clients can reliably administer at home.
The pharmacological toolkit for veterinary pain management has expanded substantially in recent years, and the evidence base for multimodal protocols continues to grow. Our network of board-certified specialists at VESPECON supports partner practices in building and refining those protocols through tele-consultation, diagnostic imaging interpretation, and ongoing case collaboration. Practices looking to elevate their chronic pain management capabilities can connect with us to learn about partnership.
Why Single-Drug Approaches Fall Short
Pain is not a single mechanism. Osteoarthritis involves peripheral sensitization at the joint, central sensitization in the dorsal horn, and often a neuropathic component as the disease progresses. A patient managed on an NSAID alone is having one pathway addressed while others continue unchecked. This is the core rationale for multimodal therapy: using drugs and modalities that work through different mechanisms in combination produces additive or synergistic effects at lower doses of each individual agent, which reduces adverse effect burden while improving efficacy.
The practical challenge is matching the protocol to the patient. A geriatric cat with concurrent chronic kidney disease, hypertension, and osteoarthritis requires a very different approach than a large-breed dog with degenerative joint disease and no comorbidities. This is where our clinical advisory network adds the most value- not in identifying that a patient is in pain, but in helping build the right combination for the specific clinical picture.
The Full Pharmacological Toolkit
NSAIDs: Choosing the Right Agent for the Patient
NSAIDs remain first-line for most arthritis patients where renal and hepatic function support their use, but the class is not monolithic. The newer generation of non-COX inhibitors is expanding options for patients who have not tolerated traditional NSAIDs.
Advanced pain management protocols in palliative and hospice contexts emphasize the importance of selecting the least systemically burdensome option that still provides meaningful relief. Grapiprant (Galliprant) targets the EP4 prostaglandin receptor rather than inhibiting COX enzymes, which means it avoids the GI and renal risks associated with COX inhibition. For patients with mild to moderate renal compromise or GI sensitivity where traditional NSAIDs are a concern, grapiprant offers a meaningful alternative. In cats, meloxicam at carefully calibrated long-term doses remains the most evidence-supported NSAID option, though the therapeutic window is narrow and regular monitoring is non-negotiable.
Key considerations when selecting an NSAID: washout periods before switching agents, renal and hepatic baseline panels, blood pressure in hypertensive patients, and client compliance with monitoring schedules.
Monoclonal Antibody Therapies: The Mechanism Shift
Librela (bedinvetmab) and Solensia (frunevetmab) represent the most significant shift in chronic pain management for companion animals in recent years. Both target nerve growth factor (NGF), a key mediator of peripheral sensitization, through anti-NGF monoclonal antibodies rather than through prostaglandin suppression. This mechanism offers several clinical advantages: no GI or renal burden, no required washout between agents, and no hepatic metabolism concerns that complicate so many other drug choices in geriatric patients.
For patients where NSAIDs are contraindicated or where NSAID monotherapy has been insufficient, monoclonals provide a mechanistically distinct option that can be used concurrently with most other analgesic agents. Monthly injectable administration also sidesteps oral compliance challenges common in geriatric cats and small dogs. The evidence base continues to mature, and real-world clinical data from partner practices has consistently reinforced the published trial results.
Gabapentinoids: Gabapentin and Pregabalin
Gabapentin is now standard in most multimodal chronic pain protocols, particularly for patients with a neuropathic component. It modulates voltage-gated calcium channels in the dorsal horn, reducing the release of excitatory neurotransmitters involved in central sensitization. In cats, it is one of the better-tolerated long-term analgesic options and can be compounded into palatable formulations when oral administration is challenging.
Pregabalin has a more predictable pharmacokinetic profile than gabapentin, with more reliable bioavailability, and may offer better efficacy in patients where gabapentin has provided only partial benefit. It is more expensive and less widely used in veterinary practice, but in complex neuropathic pain cases, the switch is worth considering. Sedation is the most common limiting adverse effect of both drugs, and dose titration from a low starting point is advisable, particularly in elderly patients.
Amantadine: NMDA Receptor Antagonism
Amantadine is one of the most underutilized agents in the veterinary chronic pain toolkit. As an NMDA receptor antagonist, it targets the central sensitization that develops in chronic pain states, which NSAIDs and other peripheral analgesics do not address. In patients with wind-up or established central sensitization, adding amantadine to an existing NSAID regimen often produces noticeable improvement even when dose escalation of the NSAID has plateaued.
Typical dosing in dogs is once daily, often combined with an NSAID. In cats, it is used more cautiously, at lower doses. The drug has a narrow evidence base in veterinary medicine by pharmaceutical standards, but clinical experience broadly supports its use in chronic, refractory cases. Pain relief options in companion animals increasingly position amantadine as a standard adjunct in complex multimodal protocols rather than a last resort.
Tricyclic Antidepressants and Other Adjuncts
Amitriptyline and other TCAs are occasionally used in veterinary patients for their analgesic properties in neuropathic pain, acting through multiple mechanisms including sodium channel blockade, norepinephrine and serotonin reuptake inhibition, and NMDA receptor modulation. Use is most documented in cats with idiopathic cystitis but extends to neuropathic pain in other contexts. Anticholinergic adverse effects, including urine retention and sedation, limit use in some patients.
Low-dose naltrexone (LDN) has attracted increasing interest in veterinary medicine for its immunomodulatory and potentially analgesic properties. At very low doses, transient opioid receptor blockade appears to upregulate endogenous opioid production and modulate microglial activation involved in central sensitization. Evidence in veterinary patients is preliminary but growing, and in complex, refractory chronic pain cases with an inflammatory component, LDN is a reasonable adjunct to discuss with our clinical advisory team.
Opioids and Tramadol: Appropriate Use in Chronic Pain
Full and partial opioid agonists have a more limited role in outpatient chronic pain management than in acute or perioperative settings, but they remain relevant for specific patient presentations. Buprenorphine is the most commonly used outpatient opioid in cats and can be administered transmucosally, which significantly improves client compliance. Hydrocodone combination products have been used in dogs, though their analgesic efficacy in chronic pain is debated and abuse potential considerations apply.
Tramadol deserves specific mention because it continues to be prescribed routinely in dogs despite evidence that dogs metabolize it differently from humans and may not produce meaningful concentrations of the active M1 metabolite. Its analgesic efficacy in dogs is questioned by the current evidence base. In cats, tramadol metabolism is more favorable and it may provide genuine benefit, though individual response varies considerably.
Ketamine: Low-Dose Infusions and Outpatient Protocols
Low-dose ketamine infusions in a clinical setting are valuable for patients with refractory chronic pain, particularly where central sensitization is prominent. Sub-anesthetic ketamine acts primarily through NMDA receptor antagonism and can provide meaningful pain relief and central sensitization reset in patients who have not responded adequately to oral multimodal protocols. While not a true outpatient modality, periodic clinic-based infusions can extend the efficacy of the home oral protocol between visits and are particularly valuable in hospice and palliative contexts where quality of life optimization is the primary goal.
Acetaminophen: A Species-Critical Distinction
Acetaminophen is an analgesic option in dogs only. It should never be used in cats under any circumstances, where even small doses cause life-threatening methemoglobinemia. In dogs, acetaminophen provides analgesia and antipyretic effects without GI burden, which makes it a useful component of multimodal protocols where GI sensitivity or prior NSAID intolerance is a factor. Dosing in dogs is typically every 8 to 12 hours, with caution in patients with hepatic disease.
Nutraceuticals: Evidence-Based Selection
The nutraceutical market is overcrowded with underevidenced products, which makes evidence-based selection important. Omega-3 fatty acids (EPA and DHA) have the strongest evidence base for reducing synovial inflammation and are a reasonable adjunct in all osteoarthritis patients. Dosing matters: therapeutic benefit requires EPA/DHA at approximately 75 to 100 mg/kg combined per day in dogs, which is substantially higher than most commercial supplements provide at label dosing.
Glucosamine and chondroitin remain widely used despite mixed evidence. Their most defensible role is as part of a broader multimodal strategy rather than as standalone therapy. Green-lipped mussel preparations have some supporting evidence. Palmitoylethanolamide (PEA) is attracting increasing interest for its endocannabinoid-modulating anti-inflammatory properties, with a growing body of veterinary literature supporting use in chronic pain.
Cannabinoids: Where the Evidence Stands
CBD and hemp-derived products are increasingly requested by clients and used by practitioners, and the evidence base, while still developing, has grown meaningfully. CBD does not appear to act through CB1 or CB2 receptors at standard doses but instead modulates TRPV1 channels and influences endocannabinoid reuptake, which may explain observed anti-nociceptive and anti-inflammatory effects. A Cornell study in dogs with osteoarthritis showed reduced pain scores and increased mobility at 2 mg/kg twice daily of a hemp-derived CBD oil, which remains the most cited controlled trial in veterinary chronic pain.
The practical challenges are product quality variability, limited regulatory oversight, and absence of approved veterinary products in most markets. For practitioners choosing to use cannabinoids, recommending products with documented COA and third-party testing for cannabinoid content and contaminant absence is essential. Adverse effects are generally mild at standard doses, with sedation and GI upset the most commonly reported.
Emergency Pain Management Kits for Chronic Pain Patients
An underrecognized component of comprehensive chronic pain management is preparing clients for acute pain crises at home. Senior patients with managed chronic pain are at risk for sudden escalations, acute on chronic exacerbations, pathological fractures in cancer patients, and disc events in predisposed breeds. Having a prescribed emergency kit at home, discussed and assembled proactively during a stable visit, can meaningfully improve outcomes when acute deterioration occurs outside clinic hours.
A typical emergency kit for a high-risk chronic pain patient might include a short course of a fast-acting analgesic such as buprenorphine for cats or a tramadol/NSAID combination for dogs, clear written instructions for dosing triggers and when to call versus when to administer, and guidance on when the situation warrants emergency transfer. Establishing this protocol at a stable visit rather than during a crisis prevents under-treatment in the acute period and gives clients confidence rather than panic when something changes overnight. Our clinical advisory team can help partner practices develop standardized emergency kit protocols for their chronic pain population.
Rehabilitation and Integrative Therapies
Pharmacological management alone addresses the biochemical dimension of pain. Physical rehabilitation and integrative modalities work through distinct mechanisms and the combination produces better outcomes than either approach independently.
Cold laser therapy reduces inflammation, stimulates tissue repair, and modulates pain signaling at the cellular level. It is non-invasive, well-tolerated, and particularly effective for osteoarthritis and post-surgical recovery. Many of our partner practices have integrated laser as a standard component of their senior pain protocols.
Acupuncture modulates pain through the nervous system, promotes endogenous opioid release, and improves regional circulation. Its particular value is in neuropathic pain presentations and patients where medication options are constrained by organ disease. Traditional Chinese Veterinary Medicine offers a complementary framework integrating acupuncture, food therapy, and herbal medicine.
Environmental and assistive device recommendations round out the protocol. Non-slip surfaces, ramps, raised food bowls for cervical arthritis patients, and low-entry litter boxes for cats are low-cost, high-impact recommendations to include in every discharge summary for a chronic pain patient. Assistive devices including support harnesses and mobility slings extend the quality of life of patients who would otherwise be significantly limited.
When Chronic Pain Becomes an Acute Crisis
Most chronic pain is managed on an outpatient basis, but escalation patterns warrant clear protocols. Advise clients to contact the practice immediately for: sudden inability to stand or walk, hind limb dragging, rapid or labored breathing, severe swelling of a joint or limb, continuous vocalization, or repeated unproductive straining. These presentations represent a change in kind from chronic pain management and may indicate acute spinal cord compression, pathological fracture, or organ decompensation requiring urgent evaluation. Our specialty hospital network supports timely case transfers when presentations exceed what a general practice can manage in-house.
Frequently Asked Questions About Multimodal Pain Protocols
How do I differentiate pain-related behavioral changes from cognitive dysfunction in senior patients?
Both can produce similar presentations and frequently co-occur. Pain-related changes tend to be positional, worse after rest, improved with warm-up, and reactive to palpation. CDS presents with disorientation, disrupted sleep-wake cycles, and house soiling without clear physical cause. A structured pain assessment alongside a validated CDS screening tool gives the clearest differential picture. Our internal medicine specialists can assist with complex cases where separation is difficult.
Are Librela and Solensia appropriate for patients with concurrent organ disease?
Both work through NGF targeting rather than COX inhibition and do not carry the same renal or hepatic monitoring requirements as NSAIDs, making them particularly relevant where traditional NSAIDs raise safety concerns. Individual patient assessment still applies, and our clinical advisory team is available for case-specific consultation when comorbidities complicate the decision.
How should partner practices structure case collaboration with VESPECON?
Cases can be submitted with clinical notes, imaging, and a specific clinical question. A board-certified specialist reviews the case and provides a structured response with protocol recommendations. Ongoing collaboration for complex cases is available. Contact us to discuss how the partnership model works in practice.
What is the evidence base for acupuncture and laser in chronic pain management?
Both have a meaningful and growing evidence base in veterinary medicine and are most effective as part of a multimodal plan that includes appropriate pharmaceutical management rather than as standalone therapies. For practices new to integrative modalities, our specialists can advise on when and how to incorporate them into existing chronic pain protocols.
Better Pain Management Starts with Better Support
The patients who benefit most from multimodal chronic pain management are not receiving it, largely because building and adjusting those protocols requires more specialist depth than a general practice can maintain across every case type in daily workflow. That is precisely the gap VESPECON is built to close.
Through tele-consultation, imaging interpretation, and ongoing case collaboration, partner practices can offer their senior patients the full depth of specialty expertise without requiring clients to navigate a separate referral system. Practices ready to elevate their chronic pain management capabilities can learn more about partnership or connect with our team today.
Leave A Comment